ARAY Stock — Accuray Incorporated

Accuray Incorporated (ARAY)

Updated October 16, 2026.

ARAY is a Stock. Total return is -99.5% over the past 19.7 years, 753.9 points behind SPY at 654.4%.

Accuray Incorporated designs, develops, and sells robotic radiosurgery and radiation therapy systems for treating tumors throughout the body, with its primary offerings including the CyberKnife platform for stereotactic radiosurgery and the TomoTherapy platform for helical radiation treatment. The company serves hospitals and treatment facilities globally, generating revenue through direct sales of medical devices and related professional services including installation, training, and customer support. Accuray does not currently have an established distribution program.

ARAY performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.5% over the past 19.7 years, 753.9 points behind SPY at 654.4%. Over the past year its total return — price change plus distributions reinvested — is -91.1%. Its deepest 1-year drawdown was 91.2%.

ARAY key facts

Asset type

Stock

Asset class

Equity

Inception date

02/08/2007

Distribution frequency

None

Last close

$0.16 (as of 2026-10-16)

Market cap

$18,596,700

Average volume

1941235.0

Beta

1.419

Payout ratio

0.0%

Forward P/E

94.3396

EPS

$-0.40

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARAY risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 91.2%.

Who may consider ARAY — and who may not

It is a weaker fit for investors who need monthly cash flow (ARAY does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ARAY

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions